In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.
While both Gilead and AbbVie have been achieving miraculous cure rates with their hepatitis C drugs in clinical trials, Gilead's regimen of one pill per day for eight weeks vs. AbbVie's six pills a day for 12 weeks could put AbbVie's treatment in a very tight spot in terms of competition. Gilead is also striving to be first of the two to market by accelerating its timeline to get an earlier approval. Could this spell a major derailment for AbbVie? David discusses the two treatments, and gives investors an outlook for just how bad for this might be AbbVie .
Two revolutionary biotechs
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Could AbbVie's Hepatitis C Treatment Be in Trouble? originally appeared on Fool.com.
David Williamson owns shares of AbbVie. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.